



Brigham and Women's Hospital

Founding Member, Mass General Brigham

CARDIOGENIC SHOCK

Erin A Bohula, MD Dphil
Critical Care Cardiologist
Cardiovascular Division
Brigham and Women's Hospital
Assistant Professor
Harvard Medical School



Erin Bohula, MD, DPhil



Harvard Medical School

Medicine Residency @ BWH

Cardiovascular Medicine Fellowship @BWH

Critical Care Medicine Fellowship @ BWH

Assistant Professor of Medicine@ HMS

Director, Critical Care Cardiology Fellowship Training
Pathway @ BWH

Investigator @ TIMI Study Group

- Clinical focus: Critical Care Cardiology
- Research focus: Cardiovascular Outcomes Trials in Critical Care Cardiology and Cardiometabolic Disease



Relevant Disclosures

- Research grant to my institution
 - Amgen, Merck, Eisai, Astra Zeneca, Novartis, The Medicines Company
- Honoraria for CME programs
 - Medscape, Merck, Servier
- Consultant
 - Scleroderma Foundation, Novo Nordisk, CeleCor, Kowa



Objectives: Cardiogenic Shock

1. Review the updated definitions of cardiogenic shock
2. Discuss the heterogeneous etiologies of cardiogenic shock and the implications for survival
3. Review management principles and algorithmic approach



Case

- 45yo M with recent smoking history (1 pack per wk) admitted with SOB, orthopnea, PND, abd distension.
- PE: HR 105, BP 120/92, 95% RA, JVP 15cm, no murmurs, +S3, b/l LE edema
- Labs: Cr 2.5, AST 750, Lactate 8
- EKG: ST, Q in I, aVL, V1-3
- Echo: EF 20%, mild LV dilation, mod central MR, mod RV dysfunction, severe TR





RCTs for P2Y12 inhibition in ACS/PCI

CURE (N=12,562)

The New England Journal of Medicine

EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION

PLATO (N=18,624)

The NEW ENGLAND
JOURNAL of MEDICINE

ESTABLISHED IN 1812

SEPTEMBER 10, 2009

VOL. 361 NO. 11

CLARITY-TIMI 28 (N=3,491)

JO

ESTABL

Addition
for M

N=59,430

N=0 with Cardiogenic Shock

(N=11,145)

JOURNAL of MEDICINE

TRITON-TIMI 38 (N=13,608)

The NEW ENGLAND
JOURNAL of MEDICINE

ESTABLISHED IN 1812

NOVEMBER 15, 2007

VOL. 357 NO. 20

Prasugrel versus Clopidogrel in Patients
with Acute Coronary Syndromes

ORIGINAL ARTICLE


Effect of Platelet Inhibition with Cangrelor
during PCI on Ischemic Events



RCTs in Cardiogenic Shock

Total N~2,700

Currently ~3,800:
+ DOREMI (192)
+ ECMO trials (~560)
+ DanGer Shock (355)



Where Does That Leave Us?

- Pathophysiologic principles
- Extrapolation from non-critical CV pts
- Extrapolation from MICU or SICU pts



What is the current status for cardiogenic shock?



BRIGHAM AND
WOMEN'S HOSPITAL
| Heart & Vascular Center |



TIMI Study Group




Critical Care Cardiology
Trials Network



HARVARD MEDICAL SCHOOL
TEACHING HOSPITAL

Indications for Intensive Care



Historical [Trial] Definitions of CS

	Hypotension	No Hypotension
Hypoperfusion	✓	X
No Hypoperfusion	X	X

Van Diepen S et al. Circ 2017;136.



BRIGHAM AND
WOMEN'S HOSPITAL
| Heart & Vascular Center |



TIMI Study Group



HARVARD MEDICAL SCHOOL
TEACHING HOSPITAL

SHARC Criteria for CS

CS Definition

Cardiac disorder with evidence of hypoperfusion

Hypo- perfusion Definition

- Elevated lactate (>2 mmol/L)
- Acute kidney injury (creatinine $\geq 2\times$ ULN) or oliguria (UOP $< 0.5\text{ml/kg/hr}$)
- Acute hepatic injury (ALT $>3\times$ ULN)
- Cool or mottled extremities
- Altered mental status not explained by an alternative cause

Waksman R et al. Circ 2023;148(14).



BRIGHAM AND
WOMEN'S HOSPITAL

| Heart & Vascular Center |



TIMI Study Group



HARVARD MEDICAL SCHOOL
TEACHING HOSPITAL

SHARC Criteria for CS

CS
Definition

Cardiac disorder with evidence of hypoperfusion

Subtypes

Hypotensive CS

- SBP <90 mmHg for ≥30 min, or
- Vasopressors, inotropes and/or MCS to maintain SBP ≥90 mmHg

Normotensive CS

- SBP ≥90 mmHg without vasopressors, inotropes or MCS

Optional
Criteria

$CI \leq 2.2 \text{ L/min/m}^2$

$CI \leq 2.2 \text{ L/min/m}^2$ and SVR
index >2200 dynes/cm/sec-
5/m²

Waksman R et al. Circ 2023;148(14).



BRIGHAM AND
WOMEN'S HOSPITAL

| Heart & Vascular Center |




TIMI Study Group





HARVARD MEDICAL SCHOOL
TEACHING HOSPITAL

Cardiogenic Shock Etiologies/Subtypes



Epidemiology



**Patients are older and with more
comorbidities**

Redfors. Int J Cardiol. 2015.



BRIGHAM AND
WOMEN'S HOSPITAL

| Heart & Vascular Center |




TIMI Study Group



HARVARD MEDICAL SCHOOL
TEACHING HOSPITAL

Contemporary Epidemiology



Berg et al. *European Heart Journal: Acute Cardiovascular Care*. 2024(13):709-714.



BRIGHAM AND
WOMEN'S HOSPITAL

| Heart & Vascular Center |




TIMI Study Group



HARVARD MEDICAL SCHOOL
TEACHING HOSPITAL

Shock Spiral



Adapted from Reynolds et al. *Circulation* 2008;117(5):686.



BRIGHAM AND
WOMEN'S HOSPITAL

| Heart & Vascular Center |



TIMI Study Group



HARVARD MEDICAL SCHOOL
TEACHING HOSPITAL

High vs Low SVR State

		Volume Status	
		Wet	Dry
Peripheral Circulation	Cold	Classic Cardiogenic Shock (↓CI; ↑SVRI; ↑PCWP)	Euvolemic Cardiogenic Shock (↓CI; ↑SVRI; ↔PCWP)
	Warm	Vasodilatory Cardiogenic Shock or Mixed Shock (↓CI; ↓/↔SVRI; ↑PCWP)	Vasodilatory Shock (Not Cardiogenic Shock) (↑CI; ↓SVRI; ↓PCWP)

Van Diepen. Circulation. 2017.



BRIGHAM AND
WOMEN'S HOSPITAL

| Heart & Vascular Center |



TIMI Study Group




HARVARD MEDICAL SCHOOL
TEACHING HOSPITAL

Uni- or Bi-Ventricular Failure?

Hemodynamic Profiles of Various Forms of Shock					
Type of shock	RAP	PCWP	RAP/ PCWP	CO	PAPi
1° L-sided	nl or ↑	↑	<0.8	↓	>0.9
1° R-sided	↑	nl or ↓	>0.8	↓	≤0.9
Biventricular	↑	↑	>0.8	↓	≤0.9

*RAP, right atrial pressure; PCWP, pulmonary capillary wedge pressure; CO, cardiac output;
Pulmonary artery pulsatility index (PAPi) = (PA systolic - PA diastolic) / RA mean*

Hemodynamic Predictors of CS Mortality



Predictors of High Mortality:

- Low arterial tone (low SVR)
- RV dysfunction

Berg et al. *European Heart Journal: Acute Cardiovascular Care*. 2023(12):651-660.



BRIGHAM AND
WOMEN'S HOSPITAL

| Heart & Vascular Center |



TIMI Study Group






HARVARD MEDICAL SCHOOL
TEACHING HOSPITAL



High Risk: AMI-CS and de novo HF-CS



Cardiogenic Shock Admissions (N=2093 from 2017-2020)




An Academic Research Organization of
Brigham and Women's Hospital and Harvard Medical School

Bhatt A*, Berg D* et al. JCF. 2021.



High Risk Sub-types



Common Language: Cardiogenic Shock Staging

SCAI Shock Stages (<i>Cath CVI</i> 2019;94:29)					
Stage	Description	BP	Exam	Labs	Hemodyn.
At risk	MI, ADHF	nl	nl	nl	nl
Beginning	Relative HoTN; tachycardia; w/o hypoperfusion	SBP <90, MAP <60, or >30 mmHg ↓ from baseline	↑ JVP, crackles, extrem warm	nl	↑ PCWP CI ≥2.2
Classic	Hypoperfusion that requires intervention	SBP <90, MAP <60, or requiring drugs/device to maintain BP	↑ JVP, crackles, extrem cool & mottled, ↓ UOP	↑ Cr lactate ≥2 ↑ LFTs	↑ PCWP CI <2.2 CPO ≤0.6
Deteriorating	Failing to respond			↑↑ Cr, lactate, & LFTs	
Extremis	Near or in cardiac arrest			lactate ≥5 pH <7.2	

Pocket Cardiology, Ginder, Bohula and Sabatine



BRIGHAM AND
WOMEN'S HOSPITAL

| Heart & Vascular Center |




TIMI Study Group



HARVARD MEDICAL SCHOOL
TEACHING HOSPITAL

Variable Mortality by CS Staging



Lawler et al. Critical Care Med. 2021



BRIGHAM AND
WOMEN'S HOSPITAL

| Heart & Vascular Center |



TIMI Study Group



HARVARD MEDICAL SCHOOL
TEACHING HOSPITAL 24

What evidence-based interventions can we offer?



BRIGHAM AND
WOMEN'S HOSPITAL

| Heart & Vascular Center |




TIMI Study Group




HARVARD MEDICAL SCHOOL
TEACHING HOSPITAL

Interrupting the Shock Spiral



Adapted from Reynolds et al. Circulation 2008;117(5):686.

Mortality Benefit of Early Revascularization in CS



No. at risk

Early revascularization	152	56	42	33	18	3
Initial medical stabilization	150	38	29	18	9	2

- 302 pts with STEMI and CS
- Early revasc w/in 6 hrs vs med Rx followed by prn revasc
- Survival
 - 30 d: 53.3% vs 44.0% ($p=0.11$)
 - 1 yr: 46.7% vs 33.6% ($p<0.03$)
 - 6 yr: 32.8% vs 19.6% ($p=0.03$)

Hochman JS, Sleeper LA, Webb JG, et al: JAMA 295(21):2511, 2006



BRIGHAM AND
WOMEN'S HOSPITAL

| Heart & Vascular Center |




TIMI Study Group



HARVARD MEDICAL SCHOOL
TEACHING HOSPITAL

CS due to STEMI Case Fatality Rate Decreasing Over Time

157,892 pts with CS due to STEMI in Nationwide Inpatient Sample from 2003-2010



Kolte D et al: JAMA 2014



BRIGHAM AND
WOMEN'S HOSPITAL

| Heart & Vascular Center |




TIMI Study Group



HARVARD MEDICAL SCHOOL
TEACHING HOSPITAL

CULPRIT-SHOCK

706 pts with CS due to AMI (61% STEMI/39% NSTEMI) and MVD
Rx: Immediate MV PCI vs Culprit-Only +/- Staged PCI



Thiele H et al. NEJM 2017;377(25).



BRIGHAM AND
WOMEN'S HOSPITAL

| Heart & Vascular Center |




TIMI Study Group



HARVARD MEDICAL SCHOOL
TEACHING HOSPITAL

CULPRIT-SHOCK



Thiele H et al. NEJM 2017;377(25).



BRIGHAM AND
WOMEN'S HOSPITAL

| Heart & Vascular Center |



TIMI Study Group



HARVARD MEDICAL SCHOOL
TEACHING HOSPITAL

Immediate Multi-vessel PCI in Shock Not Recommended

ESC STEMI Guidelines 2017 → Revascularization Guidelines 2018

STEMI (NSTEMI), Cardiogenic Shock

2017

2018



BRIGHAM AND
WOMEN'S HOSPITAL

| Heart & Vascular Center |




TIMI Study Group



HARVARD MEDICAL SCHOOL
TEACHING HOSPITAL

Interrupting the Shock Spiral

Improve global
perfusion?



Adapted from Reynolds et al. *Circulation* 2008;117(5):686.



BRIGHAM AND
WOMEN'S HOSPITAL

| Heart & Vascular Center |



TIMI Study Group



HARVARD MEDICAL SCHOOL
TEACHING HOSPITAL

Vasoactives


Pure vasopressors – Incr SVR

Inopressors – Incr CO, Incr SVR

Inodilators – Incr CO, decr SVR

Vasoactive Drugs							
Drug	Receptors	MAP	HR	CO	SVR	PVR	Comment
Pure vasopressors							
Phenylephrine	Pure α_1	$\uparrow\uparrow$	$\downarrow\downarrow^a$	\downarrow^a	$\uparrow\uparrow\uparrow$	$\uparrow\uparrow$	
Vasopressin	V_1 & V_2	$\uparrow\uparrow$	$\downarrow\downarrow^a$	\downarrow^a	$\uparrow\uparrow\uparrow$	\leftrightarrow	Consider if refractory to catechols. Attractive if RV dysfxn or PHT.
Inopressors (relative pressor vs. inotropy depends on drug & dose)							
Norepinephrine	$\alpha \gg \beta_1$	$\uparrow\uparrow$	\leftrightarrow/\uparrow	\leftrightarrow/\uparrow	$\uparrow\uparrow\uparrow$	\leftrightarrow/\uparrow	More pressor than inotrope. Fewer tachyarrhythmias than w/ dopa and mortality at least as good if not better.
Epinephrine							
Low-dose	β_1 & $\beta_2 > \alpha$	\uparrow	$\uparrow\uparrow$	$\uparrow\uparrow$	\downarrow	\leftrightarrow	Inotrope
High-dose	$\alpha > \beta$	$\uparrow\uparrow$	$\uparrow\uparrow$	$\uparrow\uparrow$	$\uparrow\uparrow$	\uparrow	Inotrope+pressor
Dopamine ^b							
Low-dose	D	\leftrightarrow	\leftrightarrow/\uparrow	\leftrightarrow/\uparrow	$\leftrightarrow/\downarrow$	\leftrightarrow	
Medium-dose	$\beta_1 > D, \alpha$	\leftrightarrow/\uparrow	\uparrow	$\uparrow\uparrow$	\leftrightarrow	\leftrightarrow	
High-dose	$\alpha > \beta_1, D$	$\uparrow\uparrow$	$\uparrow\uparrow$	\uparrow	$\uparrow\uparrow$	\uparrow	
Inodilators							
Dobutamine	$\beta_1 \gg \beta_2, \alpha_1$	$\leftrightarrow/\downarrow$	$\uparrow\uparrow$	$\uparrow\uparrow$	\downarrow	\downarrow	\downarrow PCWP. Fast onset. Tachyphylaxis.
Milrinone	PDE ₃ inhib	$\downarrow\downarrow$	\uparrow	$\uparrow\uparrow\uparrow$	$\downarrow\downarrow$	$\downarrow\downarrow$	$\downarrow\downarrow$ PCWP; \downarrow PVR; \therefore attractive if RV dysfxn or PHT. Slow onset. Renally cleared.
Isoproterenol	β_1 & β_2	\downarrow	$\uparrow\uparrow\uparrow$	$\uparrow\uparrow$	$\downarrow\downarrow$	\downarrow	\oplus chronotrope
Pure vasodilators							
Nitroglycerin	NO \rightarrow sGC	\downarrow	\uparrow	\leftrightarrow	\downarrow	\downarrow	Venodilator \gg arteriolar dilator
Nitroprusside ^c	NO \rightarrow sGC	$\downarrow\downarrow\downarrow$	\uparrow	$\uparrow\uparrow^c$	$\downarrow\downarrow\downarrow$	$\downarrow\downarrow$	Arteriolar dilator \geq venodilator

SOAP II: Dopamine vs Norepinephrine



- **28d mortality:**
 - **52.5% for DA vs 48.5% for norepi**
 - **OR 1.17 (0.97-1.42), p=0.10**
- **Arrhythmias: 24.1% vs 12.4%**

De Backer et al. NEJM 2010;362:779.



BRIGHAM AND
WOMEN'S HOSPITAL

| Heart & Vascular Center |




TIMI Study Group




HARVARD MEDICAL SCHOOL
TEACHING HOSPITAL



SOAP II: Dopamine vs Norepinephrine



Increased signal of harm with dopamine?



Epinephrine vs Norepinephrine



● Epinephrine





TABLE 2 Serious Adverse Events and Outcomes

	Epinephrine (n = 27)	Norepinephrine (n = 30)	p Value*	Odds Ratio (95% Confidence Interval)	p Value†
Refractory shock	10 (37)	2 (7)	0.008	8.24 (1.61–42.18)	0.011
Arrhythmia	11 (41)	10 (33)	0.59	1.37 (0.47–4.05)	0.56
ECLS	3 (11)	1 (3)	0.34	3.62 (0.35–37.14)	0.28
Death	14 (52)	11 (37)	0.29	1.86 (0.65–5.36)	0.25
Death within 7 days	8 (30)	3 (10)	0.093	3.79 (0.89–16.17)	0.072
Death within 28 days	13 (48)	8 (27)	0.11	2.55 (0.84–7.72)	0.097

Values are n (%) unless otherwise indicated. Odds ratios were expressed by using the norepinephrine group as reference. *p value from the Fisher exact test. †p value from the Wald test.

ECLS = extracorporeal life support.

*Increased signal of harm with
epinephrine?*

Levy et al. JACC 2018;72:173-82.



BRIGHAM AND
WOMEN'S HOSPITAL

| Heart & Vascular Center |



TIMI Study Group




HARVARD MEDICAL SCHOOL
TEACHING HOSPITAL

DOREMI Trial

The NEW ENGLAND JOURNAL of MEDICINE

Milrinone vs. Dobutamine in Cardiogenic Shock

DOUBLE-BLIND, RANDOMIZED TRIAL



R. Mathew et al. 10.1056/NEJMoa2026845

Copyright © 2021 Massachusetts Medical Society



BRIGHAM AND
WOMEN'S HOSPITAL

| Heart & Vascular Center |



TIMI Study Group



HARVARD MEDICAL SCHOOL
TEACHING HOSPITAL


Vasopressor Take Home

- Catecholamines have not demonstrated improved survival, but in theory may “break” the shock spiral
- **Very limited** data suggests:
 - Norepinephrine may be better than dopamine and epinephrine



Interrupting the Shock Spiral

Improve global
perfusion?



Adapted from Reynolds et al. *Circulation* 2008;117(5):686.



BRIGHAM AND
WOMEN'S HOSPITAL

| Heart & Vascular Center |






TIMI Study Group



HARVARD MEDICAL SCHOOL
TEACHING HOSPITAL

MCS Devices Improve Hemodynamics



Cheng *et al. EHJ.* 2009;30:2102-2108.



BRIGHAM AND
WOMEN'S HOSPITAL

| Heart & Vascular Center |




TIMI Study Group




HARVARD MEDICAL SCHOOL
TEACHING HOSPITAL

Lack of Mortality Benefit for MCS in Most Studies


IABP-SHOCK II (AMI-CS, N=598)



LVAD vs IABP (N=100)



VA-ECMO vs Control (N=567)



Thiele *et al.* NEJM. 2012; Cheng *et al.* EHJ. 2009;30:2102-2108; Zeymer *et al.* Lancet 2023.



BRIGHAM AND
WOMEN'S HOSPITAL

| Heart & Vascular Center |




TIMI Study Group



HARVARD MEDICAL SCHOOL
TEACHING HOSPITAL

DanGer Shock: mAFP vs SOC

- 355 pts with STEMI and AMI-CS, LA ≥ 2.5 , LV EF $< 45\%$, & not comatosed
- Randomized to SOC or impella CP w/in 12 hrs of PCI, run at highest P-level for 48 hours
- Median time from symptom onset to randomization was 4.8 hrs
- Median duration of support 2.5 days
- 16% vs 21% escalated to other MCS



Moller et al. EHJ. 2024;390.



BRIGHAM AND
WOMEN'S HOSPITAL

| Heart & Vascular Center |




TIMI Study Group



HARVARD MEDICAL SCHOOL
TEACHING HOSPITAL

DanGer Shock



Moller et al. EHJ. 2024;390.



BRIGHAM AND
WOMEN'S HOSPITAL

| Heart & Vascular Center |



TIMI Study Group



HARVARD MEDICAL SCHOOL
TEACHING HOSPITAL


UNDERSTANDING APPLICATION OF DATA TO CLINICAL PRACTICE



All cardiogenic shock
4842

AMI-Shock
24% of CS

STEMI-CS
16% of CS



Presenting Lactate ≥2.5 mmol/L
73% of STEMI-CS w/ lactate

LVEF <50%
86% STEMI-CS w/lactate >2.5

Trial Exclusion Criteria (-34%)
VSD: 10
OHCA & TTM: 86
RV failure: 12
Severe Valve Dysf: 12
Severe dementia: 10

DanGer Eligible
32% of STEMI-CS
5% of all CS admissions

Practical Guidance for Management of CS



BRIGHAM AND
WOMEN'S HOSPITAL

| Heart & Vascular Center |



TIMI Study Group



HARVARD MEDICAL SCHOOL
TEACHING HOSPITAL

General Principles of CS Management

- Stabilize HD and improve end-organ perfusion via optimization of MAP (1st) and CO (2nd), while minimizing risk of pulmonary edema and systemic venous congestion
- Allow for time to treat underlying driver(s) of shock (ACS, arrhythmia, sepsis, etc.) and facilitate cardiac recovery.




Step-Wise Approach to CS Management

- Initially must correct hypotension and MAP (goal ≥ 65 mmHg), typically with inopressor (epi/dopa/levo)
- Assess degree of congestion (preload) & adequacy of perfusion (CO)
- Assess and treat reversible causes of cardiogenic shock:
 - Acute ischemia
 - Address other potential contributors: dysrhythmias, acid/base disturbances, negative inotropes (bB, CCB) and antihypertensives
- Optimize hemodynamics, **often with PAC to guide therapy**



Optimizing Hemodynamics

- **Contractility: Goal CI ≥ 2.2**
- **Afterload**
 - Minimize excess afterload to maximize SV while maintaining adequate perfusion pressure.
 - ***Typical goals: SVR ~800-1000, MAP 65-75***



My Strategy for Vasoactives in CS


Phenotype	Vasoactive Choice
Classic CS with hypotension (low CO, high SVR, low MAP)	Inopressor (NE/epi/DA) to maintain MAP, then inodilator
Vasodilatory CS with hypotension (low CO, low SVR, low MAP)	Inopressor (NE/epi/DA) +/- vasopressin to maintain MAP, then inodilator if BP room for better CO
Normotensive cardiogenic shock (low CO, high SVR, nl MAP)	Inodilator and/or pure vasodilator



Optimizing Hemodynamics

- **Preload**

- Target a preload that makes CO near maximal (ie, flat part of Starling curve) while avoiding pulmonary edema, hepatic & renal congestion
- **Typical goal PCWP <15-20** but \uparrow levels may be tolerated in chronic HF
- Prefer diuretic gtt to bolus






Other Things to Consider

- When to escalate beyond medical therapy
 - Aggressive up-front trial of medical therapy (diuretics, vasoactives)
 - Simultaneously collect data (eg place PAC at bedside or in cath lab)
 - If refractory/declining, consider rapid escalation to MCS
- ADHF involvement
 - Are there advanced options (eg durable VAD, OHT)?
- Shock team involvement
 - CICU, iCards, ADHF, CSS, ECMO




Considerations When Choosing MCS

- Physiology
 - Ventricular involvement (left vs right vs biventricular) 
- Shock severity → degree of CO support needed 
- Requirement for respiratory support
- Duration of support and desire for ambulation
- Technical & Logistical Aspects
 - Adequate access (eg, PAD)
 - Specific contraindications (eg, LV thrombus, mechanical AVR)
 - Operator availability (eg, iCards, surgery)
- Additional considerations 
 - AMI-CS vs acute decompensated HF-CS
 - Cardiogenic (\uparrow SVR) vs mixed (\downarrow SVR)




Protocol-Based Approach



Shock Team: Multicenter Observational Study

Shock Team vs No Shock Team Center Population Characteristics	
Cardiogenic shock admissions (n)	546 vs 696
AMI-CS (%)	27 vs 28
Admission lactate (mmol/L)	2.3 vs 2.3
PCWP (mm Hg)	25 vs 22
CI (L/min/m ²)	1.9 vs 2.0
CPO (W)	0.62 vs 0.64



Case Continuation

- Remote/virtual Dx: Normotensive cardiogenic shock
 - Initial treatment: Dobutamine initiation, diuresis, transfer
- Additional Studies:
 - RHC with elevated BiV filling pressures, low CO (RA 26, PCWP 25, SVR 1800, CI 1.5, PAPi 0.8, CPO 0.5).
 - Coronary angio w/o coronary disease. No EMBx done.
 - Added milrinone
 - CO, SVR, filling pressures improved. Cr, lactate and LFTs normalized
- Refined diagnosis
 - De novo HF-CS, SCAI Stage E -> D with Biventricular failure
- Course: Unable to wean off dual inotropes → advanced therapies (R tandem, surgical LVAD (HM3) with plan for bridge to OHT



MOC REFLECTIVE STATEMENT (BRIEF TAKE HOME NOTES FOR REFERENCE)

- Cardiogenic shock is defined as a cardiac disorder that results in hypoperfusion
- Cardiogenic shock is a heterogeneous disease
 - High-risk subgroups include: AMI-CS, de novo HF-CS, mixed shock (low SVR), RV dysfunction/involvement
- SCAI staging system helps to describe clinical acuity and risk of mortality
- Team-based approach is optimal
 - CICU, ADHF, ECMO, CSS, iCards
- CS treatment options
 - Coronary reperfusion, if appropriate
 - Optimize hemodynamics with medical therapy (vasoactives and diuretics)
 - If early trial of aggressive medical therapy does not stabilize patient, consider escalation to MCS



REFERENCES

- Thiele et al. EHJ. 2015
- Thiele et al. NEJM 2017;377
- Bohula et al. JAMA Cardiology. 2019
- Van Diepen S et al. Circ 2017;136
- Waksman R et al. Circ 2023;148(14).
- Redfors. Int J Cardiol. 2015.
- Berg et al. European Heart Journal: Acute Cardiovascular Care. 2024(13):709-714.
- Reynolds et al. Circulation 2008;117(5):686.
- Pocket Cardiology, Ginder, Bohula and Sabatine
- Berg et al. European Heart Journal: Acute Cardiovascular Care. 2023(12):651-660
- Bhatt A*, Berg D* et al. JCF. 2021.
- Lawler et al. Critical Care Med. 2021
- Hochman JS, Sleeper LA, Webb JG, et al: JAMA 295(21):2511, 2006
- Kolte D et al: JAHA 2014
- Thiele H et al. NEJM 2017;377(25).
- De Backer et al. NEJM 2010;362:779.
- Levy et al. JACC 2018;72:173-82.
- Mathew, R et al. NEJM 2021.
- Cheng et al. EHJ. 2009;30:2102-2108
- Thiele et al. NEJM. 2012
- Cheng et al. EHJ. 2009;30:2102-2108
- Zeymer et al. Lancet 2023
- Moller et al. EHJ. 2024;390.
- O'Brien CG et al. JACC 2024; ePub DOI: 10.1016/j.jacc.2024.08.056
- Tehrani et al. JACC HF 2021;8(11):879.
- Papolos et al. JACC 2021; 78:1309-17

